Calamos Advisors LLC grew its position in Amedisys, Inc. (NASDAQ:AMED – Free Report) by 11.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 397,347 shares of the health services provider’s stock after acquiring an additional 41,220 shares during the period. Calamos Advisors LLC owned 1.22% of Amedisys worth $36,476,000 as of its most recent filing with the SEC.
Other hedge funds also recently modified their holdings of the company. Banque Cantonale Vaudoise acquired a new position in shares of Amedisys during the first quarter worth $60,000. Covestor Ltd boosted its holdings in Amedisys by 134.2% in the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after acquiring an additional 447 shares during the last quarter. CWM LLC increased its position in Amedisys by 40.4% during the 4th quarter. CWM LLC now owns 2,629 shares of the health services provider’s stock valued at $250,000 after purchasing an additional 757 shares during the period. Mesirow Institutional Investment Management Inc. raised its holdings in Amedisys by 9.9% during the 4th quarter. Mesirow Institutional Investment Management Inc. now owns 2,844 shares of the health services provider’s stock worth $270,000 after purchasing an additional 257 shares during the last quarter. Finally, Federated Hermes Inc. raised its holdings in Amedisys by 32.9% during the 4th quarter. Federated Hermes Inc. now owns 3,518 shares of the health services provider’s stock worth $334,000 after purchasing an additional 871 shares during the last quarter. Institutional investors and hedge funds own 94.36% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on AMED shares. StockNews.com upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a research report on Saturday, May 4th. Deutsche Bank Aktiengesellschaft downgraded Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price target for the company. in a report on Monday, July 29th. Cantor Fitzgerald reissued a “neutral” rating and issued a $101.00 price objective on shares of Amedisys in a research note on Thursday, July 25th. Finally, William Blair cut Amedisys from an “outperform” rating to a “market perform” rating in a research note on Monday, July 1st. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $100.67.
Amedisys Stock Up 0.1 %
AMED traded up $0.09 during midday trading on Friday, hitting $97.56. The company had a trading volume of 313,420 shares, compared to its average volume of 326,747. The stock’s 50 day moving average price is $96.59 and its 200 day moving average price is $94.30. Amedisys, Inc. has a 52 week low of $89.55 and a 52 week high of $98.95. The company has a market capitalization of $3.19 billion, a price-to-earnings ratio of -152.44, a PEG ratio of 1.94 and a beta of 0.79. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30.
Amedisys (NASDAQ:AMED – Get Free Report) last posted its quarterly earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.10. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. The business had revenue of $591.19 million during the quarter, compared to the consensus estimate of $579.34 million. On average, research analysts anticipate that Amedisys, Inc. will post 4.6 earnings per share for the current fiscal year.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Articles
- Five stocks we like better than Amedisys
- Overbought Stocks Explained: Should You Trade Them?
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- MarketBeat Week in Review – 8/19 – 8/23
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMED – Free Report).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.